Based on the Spruce Biosciences Inc stock forecast from 2 analysts, the average analyst target price for Spruce Biosciences Inc is USD 2.17 over the next 12 months. Spruce Biosciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Spruce Biosciences Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Spruce Biosciences Inc’s stock price was USD 0.28. Spruce Biosciences Inc’s stock price has changed by -4.91% over the past week, -21.84% over the past month and -66.60% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Spruce Biosciences Inc
No recent average analyst rating found for Spruce Biosciences Inc
Company Overview Spruce Biosciences Inc
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read Less
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients...Read More
Frequently Asked Questions About Spruce Biosciences Inc (SPRB) Stock
Based on ratings from 2 analysts Spruce Biosciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on SPRB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SPRB is USD 2.17 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 1.5.
Unfortunately we do not have enough data on SPRB's stock to indicate if its overvalued.
The last closing price of SPRB's stock was USD 0.28.
The most recent market capitalization for SPRB is USD 0.01B.
Based on targets from 2 analysts, the average taret price for SPRB is projected at USD 2.17 over the next 12 months.
This means that SPRB's stock price may go up by +672.15% over the next 12 months.
We can't find any ETFs which contains Spruce Biosciences Inc's stock.
As per our most recent records Spruce Biosciences Inc has 22 Employees.
Spruce Biosciences Inc's registered address is 611 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Spruce Biosciences Inc's website at https://sprucebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Spruce Biosciences Inc (SPRB) Stock
Based on ratings from 2 analysts Spruce Biosciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on SPRB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SPRB is USD 2.17 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 1.5.
Unfortunately we do not have enough data on SPRB's stock to indicate if its overvalued.
The last closing price of SPRB's stock was USD 0.28.
The most recent market capitalization for SPRB is USD 0.01B.
Based on targets from 2 analysts, the average taret price for SPRB is projected at USD 2.17 over the next 12 months.
This means that SPRB's stock price may go up by +672.15% over the next 12 months.
We can't find any ETFs which contains Spruce Biosciences Inc's stock.
As per our most recent records Spruce Biosciences Inc has 22 Employees.
Spruce Biosciences Inc's registered address is 611 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Spruce Biosciences Inc's website at https://sprucebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SPRB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
